Cagrilintide 5mg+Semaglutide 5mg 10 mg*10vials Kit

Description

🧪 Product Profile: Cagrilintide 5mg + Semaglutide 5mg

Product Category: Research-Grade Multi-Peptide Formulation
Composition: Lyophilized blend of two metabolic peptides:

• Cagrilintide: 5mg (Amylin analogue; CAS 1415456-99-3)
• Semaglutide: 5mg (GLP-1 receptor agonist; CAS 910463-68-2)
  Physical Form: White to off-white sterile powder; reconstituted with 1-2mL sterile saline for injection.
  Storage: Stable at -20°C for 24 months; refrigerate (2-8°C) after reconstitution and use within 5 days.
  Manufacturer: Available through specialized peptide suppliers (e.g., Shenzhen Aoxi Technology, Hubei Zhaoke Bio-Chemical) with purity ≥99% (HPLC verified).

🔬 Mechanism of Synergistic Action

🌀 Cagrilintide (5mg): Amylin Analogue

• Central Satiety Regulation: Activates amylin receptors in the area postrema, suppressing appetite by enhancing meal termination signals (complementary to GLP-1’s hypothalamic action).
• Gastrointestinal Modulation: Slows gastric emptying and reduces postprandial glucagon secretion, mitigating blood glucose spikes.
• Metabolic Cross-Talk: Upregulates brown adipose tissue thermogenesis via AMPK phosphorylation, increasing energy expenditure independently of caloric restriction.

🌀 Semaglutide (5mg): GLP-1 Receptor Agonist

• Appetite Suppression: Stimulates GLP-1R in the arcuate nucleus, reducing hunger signals and food intake via POMC neuron activation.
• Glycemic Control: Enhances insulin secretion in a glucose-dependent manner; reduces hepatic glucose production.
• Gastrointestinal Effects: Delays gastric emptying to prolong satiety, with additional benefits for gut microbiota modulation.

📈 Synergistic Interactions

The combination leverages non-overlapping mechanisms to amplify weight loss:

• Dual Satiety Pathways: Amylin (area postrema) + GLP-1 (hypothalamus) create additive suppression of food-seeking behavior.
• Energy Balance Reset: Cagrilintide’s thermogenic effect complements Semaglutide’s caloric reduction, addressing both intake and expenditure.
• Reduced Tolerance Development: Preclinical data suggests combined therapy may mitigate receptor desensitization observed with long-term GLP-1 monotherapy.

🧪 Research Applications & Preclinical Data

This formulation is primarily used in experimental settings to investigate:

• Obesity Pharmacology: Evaluation of combined peptide effects on body weight regulation and metabolic parameters.
• Synergy Studies: Mechanistic research on amylin-GLP-1 cross-talk in animal models (e.g., DIO mice, non-human primates).
• Dose Optimization: Assessment of 5mg:5mg ratio efficacy compared to other combinations (e.g., 2.4mg Semaglutide + 2.4mg Cagrilintide in clinical trials).

Key Preclinical Findings (from related CagriSema trials):

• In DIO mice, combination therapy reduced body weight by 28% vs. 15% with Semaglutide alone and 12% with Cagrilintide alone (12-week treatment).
• Improved glycemic control: HbA1c reduction of 1.8% vs. 1.1% (Semaglutide monotherapy) in diabetic rodent models.

⚠️ Safety & Handling

• Research Use Only (RUO): Not approved for human or veterinary clinical use; intended for in vitro and in vivo studies.
• Adverse Event Profile: Expected transient gastrointestinal effects (nausea, diarrhea) based on individual peptide properties; requires dose-escalation protocols in animal models.
• Reconstitution: Dissolve in sterile 0.9% NaCl; avoid vigorous shaking to prevent peptide denaturation.

📊 Comparative Efficacy (Related Clinical Data)

While direct data for the 5mg+5mg formulation is limited, the clinical candidate CagriSema (Semaglutide 2.4mg + Cagrilintide 2.4mg) demonstrated:

• Phase II Results: 15.6% mean weight loss at 32 weeks vs. 5.1% (Semaglutide alone) and 8.1% (Cagrilintide alone) in obese adults (p<0.001).
• Responder Rates: 63% achieved ≥15% weight loss vs. 12% with Semaglutide monotherapy.